Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences

Elena Castro, MD, PhD, Fred Saad, CQ, MD, FRCS, FCAHS, and Martin Boegemann, MD, discuss prostate cancer in this CE activity titled "Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences." For the full presentation, please visit us at www.peervoice.com/QFE870.

1. PeerVoice

Innovation and Individualisation in mHSPC and nmCRPC:
Optimising Patient Outcomes and Experiences

Learning Objectives
Evaluate clinical trial and real-world data which informs current
evidence-based decision-making and treatment intensification in
patients with metastatic hormone-sensitive prostate cancer (mHSPC)
and non-metastatic castration-resistant prostate cancer (nmCRPC)
Differentiate between androgen receptor pathway inhibitors (ARPIs)
utilised in mHSPC and nmCRPC based on their pharmacologic profiles
and clinical evidence
Develop contemporary treatment plans for mHSPC and nmCRPC
through application of a shared clinical decision-making approach which
integrates the characteristics and preferences of individual patients

Copyright © 2010-2024, P

2. PeerVoice

Part 1 of 4: Individualising Treatment Intensification in mHSPC:
Why We Should and How We Can

Elena Castro, MD, PhD
Consultant Medical Oncologist
Hospital Universitario 12 de Octubre
Madrid, Spain

Fred Saad, CQ, MD, FRCS, FCAHS
Professor and Chairman
Department of Surgery

Director of GU Oncology
University of Montreal

Montreal, Quebec, Canada

Martin Boegemann, MD
Professor of Urooncology

Head of Division of Urooncology
University of Muenster Medical Center
Muenster, Germany

Copyright © 2010-2024, PeerVoice

3. PeerVoice

Elena Castro, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer AG; Janssen Inc; and Pfizer Inc.

Speakers Bureau participant with Astellas Pharma Inc, AstraZeneca; Bayer AG; Janssen Inc; Novartis AG; Pfizer Inc. and Sandoz AG.
Advisory Board for AstraZeneca; Bayer AG; Dalichi Sankyo Company, Limited; El Lilly and Company; Janssen Inc; Medscape, Inc.;
Merck KGaA; Merck Sharp & Dohme Corp. Novartis AG; and Pfizer Inc.

Fred Saad, CQ, MD, FRCS, FCAHS, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc: Astellas Pharma Inc, AstraZenece; Bayer AG; Janssen Inc; Merck KGaA; Novartis AG; Pfizer Inc; and
Tolmar Inc.

1 | Grant/Research Support from Astellas Pharma Inc; AstraZeneca; Bayer AG; Fusion Pharmaceuticals Inc; Janssen Inc; Merck
KGaA; Novartis AG; Pfizer Inc. and Point Biopharma Global Inc.

Speakers Bureau participant with Astellas Pharma Inc: AstraZeneca; Bayer AG; Janssen Inc. Merck KGaA; Novartis AG; and
Pfizer Inc.

Advisory Board for AbbVie Inc. Astellas Pharma Inc; AstraZeneca; Bayer AG; GSK plc; Janssen Inc; Merck KGaA; Novartis AG:
and Pfizer Inc.

Speaker or participant in accredited CME/CP for Astellas Pharma Inc: AstraZeneca; Bayer AG; Janssen Inc; Merck KGaA;
Novartis AG: and Pfizer Inc.

Martin Boegemann, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer AG.

‘Speakers Bureau participant with Bayer AG.

Advisory Board for Bayer AG.

Speaker or participant in accredited CME/CPD for Bayer AG and Orion Corporation.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

4. PeerVoice

The Prostate Cancer Landscape

Newly
diagnosed
mHSPC

Primary
progressive
mHSPC

Localised or Terminal

locally Biochemical mCRPC EEES

advanced recurrence (death)
prostate cancer

ae nmCRPC

ADT: androgen deprivation therapy; mHSPC: metastatic hormone-sensitive prostate cancer; mCRPC: metastatic castration-resistant PC;
‘amCRPC: non-metastatic CRPC.
Courtesy of Fred Saad, MO; August 2024,

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

5. PeerVoice

The Prostate Cancer Landsca

Newly
diagnosed
mHSPC

Primary
progressive
mHSPC |

Biochemical (4 Terminal
disease

recurrence \ (death)

Localised or
locally

advanced
Prostate cancer

Patients who suffer and die of prostate cancer all have mCRPC

Courtesy of Fred Saad, MD; August 2024,

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

6. PeerVoice

Life-Prolonging Phase 3 Trials in mCRPC

| N | Indication | me ENS

TAX-327° DOC/P vs mito/P 1006 mCRPC, symptomatic or not
COU-AA-302° ABI/P vs P toss MORPC fore DOC) maine symptoms
COU-AA-301 ABI/P vs P 1195 MCRPC (post-DOC)

PREVAIL* ENZA vs PBO 1717 mCRPC (pre-DOC), mild/no symptoms
AFFIRM? ENZ vs PBO (or P) 1199 mCRPC (post-DOC)

TROPIC® CABA/P vs mito/P 755 mCRPC (post-DOC)
ALSYMPCA? Radium-223 vs PBO 921 mCRPC (post-DOC or unfit for DOC)
PROfound® Olaparibvs ENZA or ABI/P 245, mCRPC post-ARPI (with HRRm)
VISION? "iLu-PSMA-617vs SOC 831 mCRPC post-ARPI(with PSMA+) and CT

[ABE abiraterone acetate; ARPI: androgen receptor pathway inhibitor, CABA: cabazitaxel: ChT: chemotherapy; DOC: docetaxel: ENZA: enzalutamide; HRRm:
homologous recombination repair mutation: "Lu: lutetium-177; mito: mitoxantrone; OS: overall survival P: predrisone: PBO: placebo; PSMA: prostate-speciic
‘membrane antigen: SOC: standard of care.

1. Tannock F et al.N Engl J Med. 2004;3511502-1512.2. Ryan CJ et al. Lancet Oncol. 2015:6:152-180. 3. Rathkopf DE et al Eur Urol. 2014:66:215-825, 4. Beer TM et al
Eur Urol. 201771151-154. 5. Armstrong AJ et al. Cencer. 2017.1232308-23IL 6. de Bono JS et al, Lancet. 2010.376:147-1154. 7. Hoskin P etal. Lancet Oncol
201415:1397-1408. 8. Hussain M et al N Engl J Med. 2020;383:2345-2357. 9, Sartor O et al. N Engl J Med. 2021385:1091-108.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

7. PeerVoice

The Prostate Cancer Landscape (Cont'd)

Newly
diagnosed
mHSPC

Primary
progressive
mHSPC
Localised or Terminal
locally Biochemical rasen
advanced recurrence ADT

(death)

prostate cancer

ADT nmCRPC

Almost all will progress to mCRPC and die of prostate cancer

Courtesy of Fred Saad, MD; August 2024,

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

8. PeerVoice

AMPEDE: Failure-Free Survival and Overall Survival

FFS and OS for newly diagnosed patients with MI in the STAMPEDE
trial control arm (ADT)

100
2
2
4 075
1 =
g 11.2 (IQR, 5.1-28.8) 02102702)
& 050 À
£
2
E 025
E
a
2
à 0.00

o 12 24 36 48 60

Time to Randomisation, mo
MB FFS event W Death

FFS:faluro-troe survival IQR: interquartile range.
James ND et al. Eur Urol. 2015;671028-1038,

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

9. PeerVoice

AMPEDE: Failur

ree Survival and Overall Survival (Co

d)

FFS and OS for newly diagnosed patients with M1 in the STAMPEDE

trial control arm (ADT)

1.00
E
“ 075
e
E
à 0.50
£
3
E 025
E
a
2
a 000

o 12 24 36 48 60
Time to Randomisation, mo
M FFS event NM Death

James NO et al. Eur Urol. 2016:67:1028-1038.

www.peervoice.com/QFE870

Copyright © 2010-2024, PeerVoice

10. PeerVoice

STAMPEDE: Prostate Radiotherapy for mHSPC

100
80
<4 Bone * 60
©
Metastases ES
= HR 0.56 (95% Cl, 0.45-0.71) HR 0.64 (95% Cl, 0.46-0.89)
o 12 24 36 48 o 12 24 36 48
Time Since Randomisation, mo Time Since Randomisation, mo
100
so
24 Bone & 60 x
5 E
Metastases Eso $
20
9, R086 (95% cı 075-058) o | HRUI2(@5%C1 099-134)
o 2 24 36 48 0. 2 24 36 48
Time Since Randomisation, mo Time Since Randomisation, mo

RT: radiotherapy.
Al A et al. JAMA Oncol. 20217:556-563,

www.peervoice.com/@FEB7O Copyright © 2010-2024, PeerVoice

11. PeerVoice

ADT + Docetaxel or ARPI

Docetaxel
100
ee MOS 76 mo
¿zo
mos 440m
dis] rosao
ey
% 20 À HR O61 (95% CI, 0.47-
0.80); ? «.001
o > [1
Bere
Time,mo
Abiraterone
100 7
so
* 60
| >
¿so
20 À HR 0.62 (95% Cl, 0.51-0.76);
P«.001
om
O06 2 28 o 0 a
Time,mo

Note: The data presented here are not derived from head-to-head trials and are for ilustrative purposes only; no direct comparison between agents should be

made.
APA: apalutamide; NSAA: nonsteroidal antiandrogen.

‘Sweeney et al. N Engl J Med. 2015 Aug 20;373:737-746. Chi KN et

Engl J Med, 2018;381 121-131
www.peervoice.com/QFE870

Po Apalutamide
M ADT + Doc CE
M ADT alone so E peo
eso] moss?
HR 0.61 | Es HR 0.65
20 4 HR 0.65 (95% Cl, 0.53-0.79);
o
[RETTTETITT.
Time, mo
Enzalutamide
ABI Proportion alive at N:
= 3° ns Maux
mr © 076 | Proportion sive OS
¿ moon
go HR 0.67
$ 025 4 HR 067 (95% CL O.52-
& 0.86);P =.002
00

o 6

2
Time,

18 24 30 36 42 48

NN Engi J Med. 2019:38113-24. Fizazi K et al. Lancet Oncol 2018;20:686-700. Davis ID et al. N

Copyright © 2010-2024, Peer

12. PeerVoice

Improving Outcomes With Systemic Therapy

The evidence is very clear

; STAMPEDE* | LATITUDES TITAN? | ENZAMET?
a 17) | (N 2)
Doc Doc boc ABIP ABIP ENZA APA ENZA
Agent (vsPBO) (VSPBO) (amC+E) (armG) (vsPBO) (vsPBO) (vsPBO) (vs NSAA)
HROS8 HRO72 HR 0.81 HR 0.61 HRO6S HRO6S HRO.65 HR 0.67
os (95% CI, (95% Cl, (95% Cl, (95% Cl, (95% Cl, (95% Cl, (95% CI, (95% Cl,

0.68-114) 0.59-0.89) 0.69-0.95) 0.49-0.79) 056-078) 053-081) _0.53-0.79) 0.52-0.86)

2013 2015 2016 2017 2017 2019 2019 2019

We had to choose between chemotherapy and ARPI

1 Gravis G et al Lancet Oncol, 2013:14149-158, 2. Sweeney CJ et al. N Engl J Med. 2015;373:737-746. 3. James ND et al Lancet. 2016:387:1163-1177. 4, James ND et al
N Engl J Med. 2017:377:338-351. 5. Fizazi ot al. N Engl J Med. 2017;377:352-360. 6, Armstrong AJ et al ESMO Congress 2021. Abstract LBA25. 7. Chi KN ot al.N Eng! J
Med. 2019:38113-24, 8. Davis 1D et ol. N Engl J Med. 2019:381121-131.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

13. PeerVoice

Can Combinations Further Improve Outcomes?

Diagnosis Systemic Treatment Final State of Disease

mCRPC
Cancer cells ADT + ARPI

D
AN > À
A
> ma <A
t 4
K« Progress delayed
ARPI-independent

clones ADT + ARPI + ChT
O ARPI-dependent
cells

Courtesy of Christian Gratzke, MD; October 2023.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

14. PeerVoice

PEACE-1: ADT/Docetaxel +/- Abiraterone

High-Volume Disease

ds Median, 5.1 y

Low-Volume Disease

Median, NE
(95% Cl, NE-NE)

80 x Y 80
Median, 3.5 y 05% Cl, 3.8-NE) x Median, NE
& 60 4 (05% cl,3.2-40) OS 2 00 (95% Cl, 47-NE)
none y
$ 40 O 40
HR 0.72 (95% Cl, 0.55-0.95); P = 019 HR 0.83 (95% Cl, 0.50-1.38); P= 66
- y r 7 r
o 1 2 3 4 5 o 1 2 3 4 5

Time Since Randomisation, y

M SOC + ABI m soc

FizaziK et al. Lancet. 2022399:1695-1707.

www.peervoice.com/QFE870

Time Since Randomisation, y

M SOC + ABI m soc

Copyright © 2010-2024, PeerVoice

15. PeerVoice

ARASENS: Docetaxel +/- Darolutamide

100

Median, NE
(95% Cl, NE-NE)

DARO + ADT + D
M DARO + ADT + DOC Median, 48.9 mo

M PBO + ADT + DOC (95% Cl, 44.4-NE)

Patients Who Survived, %

HR 0.68 (95% Cl, 0.57-0.80); P < .001
0.3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60
Time Since Randomisation, mo
DARO: darolutamide; NE: not evaluable.

‘Smith MR et al.N Eng! J Med. 2022,386:1192-142.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

16. PeerVoice

ARASENS: Docetaxel +/- Darolutamide (Cont'd)

Time to CRPC Time to First SSE
=. © I DARO + ADT + 00€ a
oe, «© M P80+ ADT + DOC ©
2ex Bo
¿5% 60 SE ©
$9 EN
228 © =
E%% zo] ross 25 20 | HROT(95% Cl, 0.54-0.94);
32 (95% Cl, 0.30-0.42);P <.001 sé P=.02
o 3 0
03 9 15 2 27 33 39 45 51 87 SE 03 9 15 2 27 33 99 45 51 87
Time Since Randomisation, mo Time Since Randomisation, mo
Time to Pain Progression az Tims te First Subsequent Artineoplastlo
zen © BEF vo PY
age 355 eo
ER 5 pS 3 fe E
FH se
222 do ad
BE 20 {HROVO 22% 20 |HRO39(85% Cl 0.33-0.46),
E”, [ESA 0.66-0.95); 282 Jem
03 9 15 21 27 33 39 45 51 57 Le | 03 9 15 21 27 33 39 45 51 57
Time Since Randomisation, mo Time Since Randomisation, mo

SSE: symptomatic skeletal events.
‘Smith MR et ol. N Engl J Med. 2022:386:1132-1142, Smith MR et al J Clin Oncol. 2022:40(6 Suppl}.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

17. PeerVoice

ARASENS: PSA Response

PSAso Undetectable PSA
89.4 896 896 896, 100

80

673
60 sm E
| 487
12 weeks 24 weeks 36 weeks S2weeks Atany time N
286
PSAgo 239 251 261
820 837 843 649 20
676
544 569 575 590 o
428 +

24weeks 36weeks 52weeks At any time

2wecks 24 weeks | 36 weeks” S2weeks “At any time Il P80+ ADT + docetaxel

Patients Achieving
PSA; Response, %

0888383
En
Patients Achieving
Undetectable PSA, %

228
338

Patients Achieving
PSAs0 Response, %
383

IE Derolutamide + ADT + docetaxel

o

PSA: prostate-specific antigen: PSAzo: 250% reduction in PSA; PSAno: 290% reduction in PSA,
Saad F et al. Eur Urol. 2024 April 20 [Epub ahead of print] DOI: 10:1016/} eururo.2024.03.036.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

18. PeerVoice

ARASENS: Undetectable PSA Is an Associated Outcome

Time to PSA Progression

Undetectable PSA at 36 wks

os

Undetectable PSA at 36 wks
2 RECI 6 Mean NE (95% Cl NE-NE)
308 5 0

Bo 07

2 os u 3 06

cs a BS .

1. Detectable PSA at 38 whe & 2
É Medion, NE (95% Cl, 24.3-NE) BE 04 Detectable PSA at 36 whe

4 03 2 03 Median, 33.3 mo (95% Cl, 29.3-NE)
5 02 J HRO.23 5 02 {HR 0.37

à 2 ](95% Cl, 0.15-0.34) @ 011 (95% Cl, 0.28-0.49)

ul 00 + 00

© 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57

Time, mo

I DARO + ADT + DOC

© 3 6 9 12 15 18 21 24 27 3033 38 39 42 45 48 51 54 57
ime, mo

I P80 + ADT + DOC

Saad F et al Rapid, Durable, and Deep PSA Response Following Addition of Darolutamide to ADT and Docetaxel in ARASENS, 2023 American Urological Association

(AUA) Annual Meeting,

www.peervoice.com/@FEB7O

Copyright © 2010-2024, PeerVoice

19. PeerVoice

ARANOTE: Study Overview

+ A global, multicenter, double-blind, randomised, phase 3 trial
+» The efficacy and safety of darolutamide in combination with standard ADT in patients with mHSPC

Secondary endpoints
Includes - OS
DARO + ADT
De novo Mt Y (n=370) + Time to CRPC
RecurentMy = Primary | * Time to initiation of
encinar i ro) E endpoint | Subsequent
ey E epee antineoplastic therapy
Disease extent ur eine + Time to PSA progression
definition PRO AD + PSA undetectable rates
Performance status ECOG PS <2 (n =185) + Time to pain progression

Stratification Safety

+ Presence vs absence of visceral
metastases, assessed by central review Event
+ Prior local therapy vs no prior local therapy

alternative ARP!

DT doublet for patients?

“(PFS assessedby contra review based on RECIST v11 riteriafor soft tissue metastases and PCWG3 criteria for bone metastases,
PFS: radiological progression-free survival
CCinicialtrial gov: NCTO4736199. Last update posted 5 September, 2024; Accessed 6 September, 2024.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

20. PeerVoice

Improving Outcomes With Systemic Therapy

TITAN’ | ENZAMET?
1052) | (N=1125)

Doc Doc Doc BYP AByP ENZA APA ENZA ASP DARO + DOC

Agent (vs PEO) (vsPBO) © (armC+E) —(armG) (vsPBO) (esPBO) (vÑsPRO) (vs NSAA) (vSOC) (vs BOC)
HROSB HRO72 HROSI MROSIHROS6 HRO66 HROSS HROS7 HROTS HROSS

os (SKI RC (SCI (95%CL © (DSRCL_ (9%CL (8S%CL (95%CL (OSXCL (9S%CL

088-114) 059-089) 069-095) 0.49-078) 056-078) 052-081) 053-079) 062-086) 059-095) 057-080)

2013 2015 2016 2017 2017

Choosing between doublet and triplet regimens

Gravis G et al. Lancet Oncol. 2013:14149-158, 2. Sweeney CJ et al. N Eng! J Med, 2015:373:737-746. 3. James ND et al Lancet, 2016:387:1163-1177. 4. James ND et al
N Engl J Med. 2017:377:338-351.5.Fizazi et al.N Eng! J Med. 2017;377:352-360. 6. Armstrong AJ et al ESMO Congress 2021. Abstract LBA25, 7. Chi KN et al.N Eng! J
Mod. 2019:38113-24. 8. Davis ID etal. N Engl J Med. 2019:381121-131 9, FizaziK ot al ESMO Congress 2021. Abstract LBAS_PR. 10. Smith M et al. N Engl J Med.
2022:386:132-1142.

www.peervoice.com/QFE870 Copyright © 2010-2024, Peer

21. PeerVoice

Network Meta-Analysis: Triplet vs Docetaxel Doublet

Volume of Disease Timing of Metastasis

Comparison Comparison Benefit | Harm
Triplet® vs doce Triplet® vs docetaxel doublet A

Overall population = Overall population SE |

High volume =— ‘Synchronous (de novo) ~

Low volume. ee Metachronous (recurrent) _———-

Triplet* vs ARPI doublet Triplet® vs ARPI doublet E

Overall population - Overall population --

High volume — ‘Synchronous (de novo) +

Low volume — Metachronous (recurrent) ——

ARPI doublet vs docetaxel doublet
Overall population
High volume
Low volume =>

HR (95% CI)

ARPI doublet vs docetaxel doublet
Overall population -

‘Synchronous (de novo) —
Metachronous (recurrent). ———
0. 08 10 15 20
HR (95% CI)

* Triplet therapy is abiraterone or darolutamide plus docetaxel and ADT in overall patient population. Triplet therapy is abiraterone plus docetaxel and ADT in high
and low volume of disease. Triplet therapy is abiraterone or darolutamide plus docetaxel and ADT in overall patient population and in synchronous (de novo)
‘metastases. Triplet therapy is darolutamide plus docetaxel and ADT in metachronous (recurrent) metastases.

Riaz IB ot al JAMA Oncol. 2023;9:636-645,

www.peervoice.com/QFE870

Copyright © 2010-2024, PeerVoice

22. PeerVoice

Network Meta-Analysis: Triplet vs Docetaxel Doublet (Cont'd)

Volume of Di e Timing of Met:

iseas astasis
Comparison Benefit Comparison Benefit ! Harm
Triplet* vs docetaxel doublet Triplet? vs docetaxel doublet :
Overall population - Overall population +

High volume => ‘Synchronous (de novo) -
Low volume += Metachronous (recurrent) A
Triplet* vs ARPI doublet i Triplet® vs ARPI doublet f
Overall population | Overall population —
High volume + ‘Synchronous (de novo) +
Low volume —— + Metachronous (recurrent) ———»

ARPI doublet vs docetaxel doublet ; ARPI doublet vs docetaxel doublet
Overall population —! Overall population

High volume -+ ‘Synchronous (de novo)
Low volume —! Metachronous (recurrent) er
0 os 10 15 20 o. os 10 15 20
HR (95% C1) HR (95% CI)

iplet therapy is abiraterone or darolutamide plus docetaxel and ADT in overall patient population. Triplet therapy is abiraterone plus docetaxel and ADT in high
and low volume of disease. “Triplet therapy is abiraterone or darolutamide plus docetaxel and ADT in overall patient population and in synchronous (de novo)
‘metastases. Triplet therapy is darolutamide plus docetaxel and ADT in metachronous (recurrent) metastases.

Riaz 8 ot al JAMA Oncol. 2023;9:636-645,

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

23. PeerVoice

Patient Case 1

Presentation, Findings, and History

Age: 72 years
Presentation: Lower back pain and abnormal DRE

ECOG PS: 0

PSA: 201 ng/mL

Bone scan: Metastases in spine, hips, and left femur

CT scan: multiple lymph node involvement and >2cm liver
metastasis

+ Gleason score: 4+5

+ History: High BP (well-controlled)

+ Social Support: Married, with two children and three grandchildren

DRE: digital rectal exam.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

24. PeerVoice

nt Case 2

Presentation, Findings, and History

Age: 47 years
Presentation: Mild back pain

ECOG: O

PSA: 102 ng/mL

Bone scan: 3 bone metastases (lumbar spine, pelvis)
CT scan: Pelvic lymph node involvement

Gleason score: 4+5

History: No comorbidities

Social Support: Married, with one child (age: 12 years)

www.peervoice.com/QFE870

Copyright © 2010-2024, PeerVoice

25. PeerVoice

APCCC Panel: Next-Generation Imagin

For patients whose mHSPC is low-volume on conventional imaging,
but high-volume on NGI

47%
treat as per 53%

high volume/ treat as per
low volume

APCCC: Advanced Prostate Cancer Consensus Conference; NGI: next-generation imaging.
Gillessen $ et al. Eur J Cancer. 2023:185:178-215.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

26. PeerVoice

What Guides Your Choice in ARPI?
Availability
Need f Experience of
monitor use
Need for
steroids

DDI

DDE drug-drug interaction.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

27. PeerVoice

Deciding Between Doublet and Triplet Therapy in mHSPC

Considerations

+ Likelihood of hormone-insensitive clones

+ Hit hard and early because prostate cancer will be the cause of death

+ Much less effective post-ARPI progression

Courtesy of Fred Saad, MD; August 2024,

Copyright © 2010-2024, PeerVoice

28. PeerVoice

Part 2 of 4: Discussing Treatment Options for mHSPC With Our Patients:
Education, Encouragement, Empowerment and Audience Q&A

Elena Castro, MD, PhD
Consultant Medical Oncologist
Hospital Universitario 12 de Octubre
Madrid, Spain

Fred Saad, CQ, MD, FRCS, FCAHS
Professor and Chairman
Department of Surgery

Director of GU Oncology
University of Montreal

Montreal, Quebec, Canada

Martin Boegemann, MD
Professor of Urooncology

Head of Division of Urooncology
University of Muenster Medical Center
Muenster, Germany

Copyright © 2010-2024, PeerVoice

29. PeerVoice

Elena Castro, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer AG; Janssen Inc; and Pfizer Inc.

Speakers Bureau participant with Astellas Pharma Inc, AstraZeneca; Bayer AG; Janssen Inc; Novartis AG; Pfizer Inc. and Sandoz AG.
Advisory Board for AstraZeneca; Bayer AG; Dalichi Sankyo Company, Limited; El Lilly and Company; Janssen Inc; Medscape, Inc.;
Merck KGaA; Merck Sharp & Dohme Corp. Novartis AG; and Pfizer Inc.

Fred Saad, CQ, MD, FRCS, FCAHS, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc: Astellas Pharma Inc, AstraZenece; Bayer AG; Janssen Inc; Merck KGaA; Novartis AG; Pfizer Inc; and
Tolmar Inc.

1 | Grant/Research Support from Astellas Pharma Inc; AstraZeneca; Bayer AG; Fusion Pharmaceuticals Inc; Janssen Inc; Merck
KGaA; Novartis AG; Pfizer Inc. and Point Biopharma Global Inc.

Speakers Bureau participant with Astellas Pharma Inc: AstraZeneca; Bayer AG; Janssen Inc. Merck KGaA; Novartis AG; and
Pfizer Inc.

Advisory Board for AbbVie Inc. Astellas Pharma Inc; AstraZeneca; Bayer AG; GSK plc; Janssen Inc; Merck KGaA; Novartis AG:
and Pfizer Inc.

Speaker or participant in accredited CME/CP for Astellas Pharma Inc: AstraZeneca; Bayer AG; Janssen Inc; Merck KGaA;
Novartis AG: and Pfizer Inc.

Martin Boegemann, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer AG.

‘Speakers Bureau participant with Bayer AG.

Advisory Board for Bayer AG.

Speaker or participant in accredited CME/CPD for Bayer AG and Orion Corporation.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

30. PeerVoice

Patient Case 3

Presentation, Findings, and History

Age: 58 years
+ Presentation: Asymptomatic prostate adenocarcinoma T4NIM1
+ ECOG:O

+ PSA: 57.4 ng/mL

+ Bone scan: Right iliac bone metastasis

+ CT scan: Bulky retroperitoneal and mediastinal adenopathy

+ Gleason score: 5+4

+ History: Smoking history (60 packs/year)

* Social Support: Married, with children (ages: 10 and 12 years),
CEO of a venture company

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

31. PeerVoice

What Do the Guidelines Say We Should Do for mHSPC Patients?

“Take bicalutamide for 4 weeks, but should |
start if Ihave an injection after 2 weeks?"

“No direct comparison between doublet and
tripletwhat would you prefer?

about treat

intenstification

it turns out that the inheritance | may leave
to my children is an increased cancer risk”

“Denosumab every 6 months, plus calcium

Bone health protection pillas

Revise potential drug- “Doctors put me on all these medications and
drug interactions now they say they may interact”

= “am too tired... and my doctor doesn't seem
to be very fit either”

“As if didn't have enough visits to hospital |
have now been referred to a cardiologist”

Courtesy of Elena Castro, MD, PRD; August 2024,

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

32. PeerVoice

wer Patients’ C

How to

erns Efficiently After Diagnosis?

+ What type and stage of prostate cancer do | have?
+ Do | need to change my lifestyle?

+ What are my treatment options?

» Is surgery an option for me?

+ What is my life expectancy?

+ Will | be in pain?

+ Is there a clinical trial available to me?

+ What side effects can | expect and how do | cope with them?
+ What is the risk of my cancer progressing after the treatment?

Courtesy of Elena Castro, MD, PRD; August 2024

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

33. PeerVoice

muy Care Should Be Individualised ——

+ Treatment algorithms can be used as a starting point, but all patients
are different and the context needs to be taken into consideration as
there are many exceptions to standard patient groupings.

mu Shared Decision-Making (|,

- The choice of treatment should be based on a thorough discussion
with the patient about potential benefits, side effects, and personal
preferences.

+ We should be able to adapt the language and the information to the
patient, so they can understand and make an informed decision.

Courtesy of Elena Castro, MD, PRD; August 2024,

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

34. PeerVoice

Part 3 of 4: Providing Patient-Centered Care for nmCRPC:
Expert Perspectives, Current Evidence, and First-Hand Experiences

Elena Castro, MD, PhD
Consultant Medical Oncologist
Hospital Universitario 12 de Octubre
Madrid, Spain

Fred Saad, CQ, MD, FRCS, FCAHS
Professor and Chairman
Department of Surgery

Director of GU Oncology
University of Montreal

Montreal, Quebec, Canada

Martin Boegemann, MD
Professor of Urooncology

Head of Division of Urooncology
University of Muenster Medical Center
Muenster, Germany

Copyright © 2010-2024, PeerVoice

35. PeerVoice

Elena Castro, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer AG; Janssen Inc; and Pfizer Inc.

Speakers Bureau participant with Astellas Pharma Inc, AstraZeneca; Bayer AG; Janssen Inc; Novartis AG; Pfizer Inc. and Sandoz AG.
Advisory Board for AstraZeneca; Bayer AG; Dalichi Sankyo Company, Limited; El Lilly and Company; Janssen Inc; Medscape, Inc.;
Merck KGaA; Merck Sharp & Dohme Corp. Novartis AG; and Pfizer Inc.

Fred Saad, CQ, MD, FRCS, FCAHS, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc: Astellas Pharma Inc, AstraZenece; Bayer AG; Janssen Inc; Merck KGaA; Novartis AG; Pfizer Inc; and
Tolmar Inc.

1 | Grant/Research Support from Astellas Pharma Inc; AstraZeneca; Bayer AG; Fusion Pharmaceuticals Inc; Janssen Inc; Merck
KGaA; Novartis AG; Pfizer Inc. and Point Biopharma Global Inc.

Speakers Bureau participant with Astellas Pharma Inc: AstraZeneca; Bayer AG; Janssen Inc. Merck KGaA; Novartis AG; and
Pfizer Inc.

Advisory Board for AbbVie Inc. Astellas Pharma Inc; AstraZeneca; Bayer AG; GSK plc; Janssen Inc; Merck KGaA; Novartis AG:
and Pfizer Inc.

Speaker or participant in accredited CME/CP for Astellas Pharma Inc: AstraZeneca; Bayer AG; Janssen Inc; Merck KGaA;
Novartis AG: and Pfizer Inc.

Martin Boegemann, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer AG.

‘Speakers Bureau participant with Bayer AG.

Advisory Board for Bayer AG.

Speaker or participant in accredited CME/CPD for Bayer AG and Orion Corporation.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

36. PeerVoice

The Prostate Cancer Landscap

Newly
diagnosed
mHSPC

Primary
progressive
mHSPC

Localised or

Terminal
locally

disease
(death)

Biochemical
recurrence

advanced
prostate cancer

ADE nmCRPC

Rising PSA 2 ng/ml higher than nadir,
with rise 225% over nadir

No radiologic evidence of metastatic

Courtesy of Fred Saad, MD; August 2024,
Scher Hl et al. J Glin Oncol. 2016:341402-1418,

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

37. PeerVoice

AR(P)I Primary Outcome: Metastasis-Free Survival

SPARTAN': Apalutamide

HR 0.28 (95% Cl,0.23-0.35); P < 0001

APA+ ADT
Median 40.5 mo

p80 + ADT
Median 166 mo 4

PROSPER?: Enzalutamide ARAMIS?: Darolutamide

HR 0.29 (95% Cl, 024-035); P <.001 HR 0.41 (95% Cl, 0:34-0:50), P <.001

wo: 10

ENZA + ADT
Median 36.6 mo

DARO + ADT
Median 40.4 mo

MFS, %
8 8 8
2

PBO + ADT
Median 18.4 mo

PBO + ADT
20] Median 14.7 mo

Without Mets
2

e

Probability of Survival

0 4 8 1 1 20 24 20 32 36 40 44
Time From Randomisation, mo

+ 72% reduction in distant
progression or death

+ 24-mo increase in MFS

00
0 6 2 6 2 © % 4

Time From Randomisation, mo

© 4 8 12 16 20 24 28 92.36 40 44 48

Time From Randomisation, mo

+ 71% reduction in distant
metastases or death

* 59% reduction in distant
metastases or death

+ 22-mo increase in MFS + 22-mo increase in MFS

Note: The data presented here are not derived from head-to-head trials and are for ilustrativo purposes only; no direct comparison between agents should be

made.
MFS: metastasis-Iree survival

1 Smith MR et al. N Eng! J Med. 2018:378:1408-1418, 2. Hussain M et al. N Eng! J Med. 2018;378:2465-2474, 3 FizaziK et al.N Engl J Med. 2019:380:1235-1246.

www.peervoice.com/QFE870

Copyright © 2010-2024, PeerVoice

38. PeerVoice

AR(P)I Secondary Outcome: Updated Overall Survival

SPARTAN!: Apalutamide

HR 0.78 (95% CI 0.64-0.96); P = .0161

PROSPER?: Enzalutamide ARAMIS*: Darolutamide

HR 073 (95% Cl, 061-0.89); P = 001 HR 0.69 (95% Cl, 0.53-0.88), P = 003

R00 100 100

$ APA+ ADT DARO + ADT

20 Median 739 mo $ RAT o NR

2 Edda PBO + ADT Ë PBO + ADT

80 | Medion 59.9 mo Median 56.3 mo ME

É so Eso

= à

2» 20 8 2

8

Bo o o
O 6 24 32 36 44 62 60 68 76 © 8 1 24 a2 06 as 62 OO G8 70 94 2 2 2% 36 44 82 60
Time From Randomisation, mo Time From Randomisation, mo Time From Randomisation, mo

+ 22% reduction in risk of
death

* 27% reduction in risk of + 31% reduction in risk of
death death

Note: The data presented here are not derived from head-to-head trials and are for ilustrative purposes only; no direct comparison between agents should be

made.

1 Small E et al. ASCO 2020. Abstract 5516. 2. Sternberg CN et al. ASCO 2020. Abstract 5515. 3. FizaziK et al. ASCO 2019. Abstract 5514.

www.peervoice.com/QFE870

Copyright © 2010-2024, PeerVoice

39. PeerVoice

Adverse Event Profiles

SPARTAN!
Apalutamide

APA
33

PROSPER?
Enzalutamide

ENZA PBO

Fatigue 46 2
Musculoskeletal
pa en | 2B

ARAMIS?
Darolutamide

DARO
Fatigue 132
Hypertension 78

PBO
2

Fatigue
Hypertension 2 2

Diarrhoea 23 15 | | Fracture 18 6 | | Cardiacarrhythmia 7.3
Fall a | | res 18 6 | | Hot flush 6
Fall 18.5
= Bone fracture 55
Nausea 20 16 Cognitive/memory 8 2 Fall i
= impairment all, including =
Arthralgia 20 83 accident E
CV events Ela $
Weight decreased 20 65 lema Weight decrease 42
Back pain 1 15 | | disease 8 2 || astnenic condition 4
Second prima Coronary art
Hot flush 15 85 Sun 5 2 er. 4

cancer disorder

Note: The data presented here are not derived from head-to-head trials and are for ilustrative purposes only; no direct comparison between agents should be
made.
Smith MR et al Eur Urol. 202179:150-158. 2 Sternberg CN et al.N Engl J Med. 2020;382:2197-2206. 8. FizaziK et al.N Engl J Med. 2020;383:1040-1049,

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

40. PeerVoice

QoL Outcomes

FACT-P PCS?

FACT-P2
Darolutamide

FACT-P!

Apalutamide Enzalutamide

2 »
© ©

LSM Change
From BL

20
Py
40 8
-60 o
2 4 6 3822 BL 17 33 49 65 81 97 16 48 80 112 144 176 End Tx
Cycle Study Time, wk Study Time, wk

FACT-P by Trial ARPI, mo PBO, mo Pvalue
SPARTAN 6.6 84 6
PROSPER 1 1:14 El,
ARAMIS 1.07 7.88 ‚0005

Note: The dato presented here are not derived from head-to-head trials and are for ilustrativo purposes only; no direct comparison between agents should be
Ket

1 Saad F et al. Lancet Oncol. 2018,19:1404-1416; Oudard $ et al Eur Urol Focus. 2022;8958-967, 2. Tombal 8 et al. Lancet Oncol, 2019.20.556-569. 3. Fi
ASCO 2019. Abstract 551.

Copyright © 2010-2024, PeerVoice

www.peervoice.com/QFE870

41. PeerVoice

Discontinuation of Treatment

RCT Data Comparative Real-World Data (USA)

Patients Who Discontinued Treatment due to Progressive Patients Who Discontinued Treatment due to AEs,
Disease, % % Most common reason for discontinuation
Apalutamide 43
PBO 74

Enzalutamid
ralutamide = Enzalutamide 144

Apalutamide 151

Darolutamide 125 Darolutamide 10.2
U PBO 253

Patients Who Discontinued Treatment due to AEs, %

Apalutamide
PBO

Enzalutamide
PBO
Darolutamide
PBO

‘Small EJ et al. ASCO 2020. Abstract 5516. Smith MR et al. Eur Urol. 202179:150-158. Sternberg CN et al. N Engl J Med. 2020,3822197-2206.Shore ND et al
‘Oncologist. 29:581-588. Morgans AK et al. ASCO 2023. Abstract 5097.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

42. PeerVoice

DEAR: ARPI Therapy, Real-World Data, and AEs

Enzalutamii

AE (n= 362)

Any AE 90 (24.9) 112 (29.3) 38 (30.2)

CNS-related AEs 54 (14.9) 75 (19.6) 20 (15.9)
Fatigue 41(11.3) 53 (13.9) 14 (111)
Dizziness 4) 11(2.9) 3 (2.4)
Cognitive disorder a) 7(18) 2 (1.6)
Fall 3 (0.8) 5 (13) 1(0.8)

Other AEs 51(14.1) 53 (13.9) 20 (15.9)
Pain 17 (4.7) 10 (2.6) 3 (2.4)
Rash 8 (2.2) 3 (0.8) 10 (7.9)
Diarrhoea 7(19) 9(2.4) 4(3.2)
Nausea 8 (2.2) 8(21) 4(3.2)
Vomiting 5 (14) 6 (1.6) o

Morgens AK et al ASCO 2023. Abstract 5097.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

43. PeerVoice

Potential DDIs With ARPIs

Medicinal Product

Apalutamide

Darolutamide

Antithrombotics

Calcium channel
blockers

Cardiac glycosides
Proton pump inhibitor
Analgesics

Hypnotics
Antipsychotics.
Antibiotics

Anticonvulsants
Statins

Clopidogrel
Dabigatran
Rivaroxaban
Warfarin
Amlodipine
Itiazem
Nifedipine, felodipine
Verapar
Digoxin
Omeprazole
Fentanyl
Diazepam
Midazolam
Haloperidol
Clarithromycin
Rifampicin
Carbamazepine
Rosuvastatin

Indicates comedication can be combined with ARPI
Indicates comedication should be administered with caution and/or dose adjustment based on efficacy/tolerability is recommended.

Oliver KM et al. nt J Urological Nursing. 202115:47-58.

www.peervoice.com/QFE870

Indicates avoidance or substitution of comedication is recommended.

Copyright © 2010-2024, Peer

44. PeerVoice

What is the Role of PSMA PET in nmCRPC

Pelvis

[N= 200
+
n=196 n=
pl
- P 1
Tr 55% N1 54% Mia 39% Mib 24% [ Mic 6% |
a =p Cervical i Ribs/
A IN | Ter
© spine Liver
>) Retro-
N peritoneal ©

ww

DIE) pelvie Ur
(O) Mesorectal/
presacral

200 with nmCRPC by conventional

PSMA PET was positive in 196/200 patients overall

Ô Peritoneal

aging underwent PSMA PET imaging

Fendier WP et al. Clin Cancer Res. 2019;25:7448-7454,

www.peervoice.com/QFE870

Copyright © 2010-2024, PeerVoice

45. PeerVoice

Outcomes Stratified by PSA Nadir and PSA Decline

Apalutamide: SPARTAN Enzalutamide: PROSPER Darolutamide: ARAMIS

PSA <0.2ng/mL ¿PSA <02 ng/mL and 20.2 ng/mL
With PSA 302 nef, PSA Decline by temo mo, 38m

© 38 mo (medion) Subgroup
3 dd 290% PSAnadE «OZ gim
8 WithoutPsA 02 nein, E © 200% PSA nad
. Le BE ao arm.
o [mozswsscomosmr.o 28.
EEE RTTTA 53 Lone dos
Time,mo 3° Time to RadielogicalProgression.d
E
Depth of PSA Reduction o PSA Response by Subgroup
MATOS pesen.
290% 739 mo radar) 05 FromRandomisation, mo

Eon
558 mo (medien)

50% to <d0K vs «SOK: HROB!(OSK.CL 047-137) P= A
200%vs (50%: HRO3T (98% CLO22-0.63}P « 001

01 6 Dm ee OO
Time,mo

Saad F ot al. Eur Urol. 2022:81184-192 Hussain M et al. J Urol. 2023; 209:532-539. Morgans AK et al. ASCO 2023. Abstract 5097.
FizaziK et al ASCO 2021 Abstract 6079.

www.peervoice.com/QFE870 Copyright © 2010-2024, Peer

46. PeerVoice

Patient Case 4

Presentation, Findings, and History

Age: 74 years

+ History: Prostate cancer diagnosed in 2017, underwent radical
prostatectomy; Pathology revealed pT3bN2; Gleason score of
4+4;1month post-surgery PSA was 1.3 ng/mL, started on ADT

+ Presentation: PSA has been rising over past 2 years

+ PSA: 3.5 ng/mL

+ PSADT: 5.5 mo

+ Bone and CT scans: Negative

+ ECOG:O

+ Comorbidities: Atrial fibrillation, currently on rivaroxaban

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

47. PeerVoice

Summary

Why intensify therapy in patients with nmCRPC early?

* Treating patients with nmCRPC earlier, even in the absence of detectable
metastases on conventional imaging, can delay progression to metastatic disease

+ Early use of novel androgen receptor inhibitors reduces the risk of metastases,
prolongs survival, and avoids the high costs associated with managing advanced
metastatic cancer

+ The upfront costs of early intervention are offset by the reduction in long-term
treatment costs, improving overall patient outcomes and cost-efficiency

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

48. PeerVoice

Part 4 of 4: Darolutamide and ADT for mHSPC:
Results From ARANOTE

Fred Saad, CQ, MD, FRCS, FCAHS
Professor and Chairman
Department of Surgery

Director of GU Oncology
University of Montreal

Montreal, Quebec, Canada

Copyright © 2010-2024, PeerVoi

49. PeerVoice

Fred Saad, CQ, MD, FRCS, FCAHS, has a financial interest/relationship or affiliation in the
form of:

Consultant for AbbVie Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer AG; Janssen Inc.; Merck
KGaA; Novartis AG; Pfizer Inc.; and Tolmar Inc.

Grant/Research Support from Astellas Pharma Inc.; AstraZeneca; Bayer AG; Fusion
Pharmaceuticals Inc.; Janssen Inc.; Merck KGaA; Novartis AG; Pfizer Inc.; and Point
Biopharma Global Inc.

Speakers Bureau participant with Astellas Pharma Inc.; AstraZeneca; Bayer AG; Janssen Inc.;
Merck KGaA; Novartis AG; and Pfizer Inc.

Advisory Board for AbbVie Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer AG; GSK plc.;
Janssen Inc.; Merck KGaA; Novartis AG; and Pfizer Inc.

Speaker or participant in accredited CME/CPD for Astellas Pharma Inc.; AstraZeneca; Bayer
AG; Janssen Inc.; Merck KGaA; Novartis AG; and Pfizer Inc.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

50. PeerVoice

ARANOTE: Study Design

+ Aglobal, randomised, double-blind, placebo-controlled, phase 3 study

DARO 600 mg bid . o
Patients (N= 669) ear Primary endpoint
+ mHSPC + rPFS by central blinded review
+ ECOG PSO-2 (n= 446)
Secondary endpoints
Stratification Factors + 0s
+ Visceral metastases + Time to initiation of
(Y/N) subsequent anticancer therapy
+ Prior local therapy PBO + ADT + Time to mCRPC
CAN) Éd + Time to PSA progression
(n=223) + Rates of undetectable PSA
(<0.2 ng/mL)
* Metastatic disease confirmed by conventional imaging method as positive **"Tc-phosphate bone scan * Time to pain progression (BPI-
or soft issueMiscerl metastases on contras -enhanced abdominal/peli/chestCT or MR scan, sr)
Seesen by contra review + Safety

PESE: Brief Pan Inventory-Shor Form.
Saad Fetal. ESMO Congress 2024. Abstract LBAGS. PeerVoke Activity; Fred Saad, CO, MD, FRCS, FCANS; September 2024.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

51. PeerVoice

ARANOTE: Primary Endpoint-rPFS

Darolutamide significantly reduced the risk of radiological progression or death by 46%

© DARO + ADT

Median 25.0 mo

10
09
0.8

2 07 (95% CI, 19.0-NR)
3
2 06
3 ae Medien follow-up: DARO: 25.3 mo; PBO: 25.0 mo.
2 sar
5 04 PBO+ADT
© 03 Median 25.0 mo
0.2 | TPFS*:HR 0.54 (95% CI, 19.0-NR)
oa | (95% Cl, 04107172
P<.0001
00
0 3 6 9 12 15 18 21 24 27 30 33 36 39
Time, mo
primary analysis occurred alter 222 events (DARO: n= 128; BBO: n= 94) HR amd 95% C were calculated using the Cox model stated on visceral metastases (V/N and prior

therapy IN)

Saad Fetal ESMO Congress 2024. AbstractLBAGS. PeerVoke Activity Fred Saad, CO, MD, FRCS, FCAHS; September 2024.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

52. PeerVoice

ARANOTE: Subgroup Analyses

RoW: Rest of word

exc

‘reat port, Cal
ses ua
En ta
Acosubgromey DE =
288 a
<medan ae
BL PSA voue an
° u.
Eco PS at at al
Caton score sat Mösnefno assessed
danois 2 om
ose volume mes
write pa
= Asian a
act HA
Omer
Europe and RoW! a
Geographicrogión Ala Es
Latin Amica a
Ye
Vmcrsimastune YO
Yes i
Prorlocalthorpy Ye
HR ad 959% lar cae rom uva anal or 7 %
vingunaratid ocres (98% co
Fovoure DO Fevours POO

Saad Fetal. ESMO Congress 2024. AbstractLBAGS. PeerVoke Activity; Fred Saad, CO, MD, FRCS, FCANS; September 2024.

www.peervoice.com/QFE870

Copyright © 2010-2024, Peer

53. PeerVoice

ARANOTE: TEAEs and Incidence Between Similar Arms

TEAES Darolutamide + ADT (n = 445) PBO+
Incidence, % EAIR/100 PY Incidence, % EAIR/100 PY

Fatigue 5.6 32 81 5.7
Mental impairment disorder 16 09 05 03
Hypertension 9.4 5.5 95 67
Cardiac arrhythmias 88 51 68 47
Coronary artery disorders 3.6 20 14 0.9
Heart failure 09 05 09 06
Falls, including accident 13 08 09 0.6
Bone fracture 4.0 23 23 15
Vasodilation and flushing 92 56 72 5.0
Diabetes and hyperglycaemia 90 53 95 67
Rash 43 24 36 24

EN: exposure-adjusted incidence ate; PY: patient years.
Saad Fet a. ESMO Congress 2024. Abstract LBAGS. PeerVoke Activity Fred Saad, CO, MD, FRCS, FCAHS; September 2024.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice

54. PeerVoice

ARANOTE: Secondary Endpoints

Darolutamide

(n = 445)
~~ fos Pa Per} _
103 081
os és» 60(26.9) AR Goa
154 143 040
Time to meRPC eu) | 8 | Gia | eas (032-051)
se 108 0.31
Time to PSA progression 93(20.9) NR (asa) 168 HH enon
Time to initiation of subsequent 68 74 040
systemic therapy for PC | EI] HN E (029-056)
k 124 072
Time to pain progression (278) NR 79(35.4) 29.9 HR (0.54-0.96)
“atthe tie primary als, OS data were mature 01 1 10
+ mn —
Forousonno Fous PO

Saad Fet al. ESMO Congress 2024. AbstractLBAGS. PeerVoice Activity; Fred Saad, CO, MD, FRCS, FCANS; September 2024.

www.peervoice.com/QFE870

Copyright © 2010-2024, PeerVoice

55. PeerVoice

ARANOTE: PSA <0.2 ng/mL; Delayed Time to PSA Progression

PSA <0.2 ng/mL at any Time

Time to PSA Progression
During Treatment ogre
100 .
E DARO +ADT
09 Median NR (95% Cl, NR-
80 ze ledian NR (95% Cl, NR-NR)
= os
x 307
5 60 2
2 62.6% 206
2 © 0s
2” $ 04
En PBO+ADT
5 +
* 18.5% & 02 THRosı Median 16.8 mo (95% Cl, 13.9-20.1)
0-1 7 (95% ci, 0.23-0.41)
9 o
DRG ADE; PBO + ADT 0 3 6 9 12 15 18 21 24 27 30 33 36 39

Time, mo

Saad Fetal ESMO Congress 2024. Abstract LBAGB, PeerVoke Activity; Fred Saad, CO, MO, FRCS, FCAHS: September 2024.

www.peervoice.com/QFE870 Copyright © 2010-2024, PeerVoice